SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is facing intense community debate as investors weigh concerns over potential dilution and future stock splits against optimism surrounding the commercial traction and insurance coverage expansion of their lead product, Tonmya. While some shareholders are selling amid downward price pressure and a history of capital raises, others are aggressively buying the dip, citing strong long-term pipeline fundamentals and recent insider share purchases as evidence of an impending turnaround.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors digest long-term Week 40 Phase 3 data, which demonstrates deepening clinical efficacy and reinforces the company's best-in-class potential for treating Hidradenitis Suppurativa. The community is actively discussing the drug's regulatory pathway toward a BLA submission and the potential for a strategic buyout, while simultaneously debating market maker activity and recent analyst upgrades that have significantly raised price targets.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is seeing significant volatility as investors weigh the company's shift toward high-performance AI data center infrastructure against macro-driven sell-offs and geopolitical instability in the Middle East. While community sentiment remains polarized, many participants are focused on the company's execution timeline for new site energization and the potential for major hyperscaler contract announcements to serve as a catalyst for recovery.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energy Corp

Bloom Energy is currently rallying as investors position the stock as a primary 'bring-your-own-power' solution for the surging AI data center buildout, further fueled by recent policy discussions surrounding energy infrastructure independence. The community is actively debating the stock's valuation and volatility, while tracking technical breakout levels and watching for institutional accumulation as the company solidifies its role in the critical power generation sector.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is currently trending as investors monitor significant debt-to-equity conversions and expansion plans for a massive new manufacturing facility, fueling intense speculation over future defense and aerospace contracts. Community sentiment remains deeply polarized, pitting long-term shareholders bullish on the company’s critical role in defense supply chains against skeptics focused on potential dilution risks and the company’s path to profitability.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is facing intense downward pressure driven by a combination of geopolitical instability in the Middle East and market FUD surrounding Google's new memory-compression technology. While the community remains deeply divided between those viewing the current valuation as a generational buying opportunity and those fearing further technical breakdowns, investors are closely watching key support levels as they navigate the disconnect between the company's strong fundamentals and persistent institutional selling.

Pelican Acquisition Corporation is a special-purpose acquisition company that aims to merge with or acquire businesses, particularly in the global technology sector. The company's primary purpose of facilitate a merger, share exchange, asset acquisition, share purchase, reorganization, or any other form of business combination with one or more businesses.

Greenland Energy Co.

Greenland Energy is capturing significant market attention following its recent NASDAQ debut and business combination, as traders speculate on the potential for massive oil reserves in the Jameson Land Basin. The community is actively debating the company's long-term exploration goals versus short-term volatility, with many monitoring volume, potential squeezes, and the involvement of experienced industry leadership.

Sigma Lithium Corp. engages in the producing of a lithium property. It focuses its project in Minas Gerais. The firm also plans to build a world-class commercial-scale lithium concentration plant. The company was founded on June 8, 2011 and is headquartered in Sao Paulo, Brazil.

Sigma Lithium Corporation

Sigma Lithium is generating significant market interest following a series of operational and financial milestones, including strong cash margins and the securing of long-term offtake agreements. Investors are actively debating the company's growth thesis and debt reduction progress, while recent momentum has been bolstered by increased lithium demand visibility and broader sector excitement regarding energy storage and electrification.

Alaska Air Group, Inc. is a holding company, which engages in the provision of air transportation services. It operates through the following segments: Alaska Airlines, Hawaiian Airlines, and Regional. The Alaska Airlines segment includes scheduled air transportation on Alaska's Boeing and Airbus jet aircraft for passengers and cargo. The Hawaiian Airlines segment refers to scheduled air transportation on Hawaiian's Boeing and Airbus aircraft for passengers and cargo. The Regional segment consists of Horizon's and other third-party carriers’ scheduled air transportation on E175 aircraft for passengers under CPAs. The company was founded in 1985 and is headquartered in Seattle, WA.

Alaska Air Group Inc.

Alaska Air Group is currently at the center of investor focus following a Q1 guidance revision that widened projected losses, driven by fuel cost headwinds and operational challenges in Hawaii and Mexico. Despite the near-term volatility, the community is actively debating the stock's valuation, highlighting its strategic positioning, long-term growth prospects, and recent heavy institutional accumulation as indicators that the shares may be undervalued.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Fannie Mae ($FNMA) is seeing intense trading activity as investors react to ongoing speculation about an exit from conservatorship, with prominent figures like Bill Ackman and Michael Burry reportedly maintaining long positions. Community sentiment remains deeply divided, with bulls pointing to potential future catalysts and institutional buying, while bears emphasize the lack of concrete news and the stock's recent volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Is Viridian Therapeutics Stock Falling Monday?

Viridian (VRDN) shares plunge 38% premarket despite positive Phase 3 TED trial data. Analysts weigh in on elegrobart's market viability.read more...

Futures, Gold Jump As Yields Fall Despite Surging Oil As Recession Fears Surpass Inflation Concerns

Futures, Gold Jump As Yields Fall Despite Surging Oil As Recession Fears Surpass Inflation Concerns Futures are higher despite continued Iran war escalation which pushed Brent higher by around 2...

<ul class="summary-bullets"><li>Viridian stated that the REVEAL-1 trial showed strong results, meeting its main goal and a key secondary goal at week 24 as measured by eye bulging.</li><li>The company stated that Elegrobart reduced eye bulging by about 54% in the four-week regimen and by 63% in the eight-week regimen, compared with roughly 18% on placebo.</li><li>Viridian stated that topline results from REVEAL-2, the second Phase 3 trial evaluating Elegrobart in patients with chronic thyroid eye disease, are expected in the second quarter of 2026.</li></ul>Viridian Therapeutics Inc. (VRDN) shares tanked more than 41% in Monday’s pre-market trade after the company announced results from its Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease.Viridian stated that the REVEAL-1 trial of Elegrobart met its primary endpoint of proptosis responder rate (PRR) with a highly statistically significant treatment effect in the four-week dosing regimen.However, the company stated that while Elegrobart was generally well tolerated in the four and eight-week dosing regimens, the phase 3 trial showed low rates of hearing impairment.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/VRDN">Viridian Therapeutics</a> trended in the ‘bullish’ territory with message volumes at ‘high’ levels at the time of writing.<h2 class="st-heading-2">What Did The Trial Reveal?</h2>Viridian stated that the REVEAL-1 trial showed strong results, meeting its main goal and a key secondary goal at week 24 as measured by eye bulging. The study also tested a different dosing schedule (every 8 weeks) versus placebo and examined other important outcomes.The company stated that Elegrobart reduced eye bulging by about 54% in the four-week regimen and by 63% in the eight-week regimen, compared with roughly 18% on placebo.However, Elegrobart showed only a slight improvement over placebo in the Clinical Activity Score (CAS), a measure of inflammation and disease activity.Viridian’s results showed that the CAS reduction to 0 or 1 was 57% in the four-week regimen and 69% in the eight-week regimen, compared with 50% in the placebo group.The company said that all complaints of adverse events in both regimens were reports of tinnitus, none of which were associated with hearing reduction.<h2 class="st-heading-2">Viridian Says Elegrobart On Track For BLA Submission In 2027</h2>The company stated that topline results from REVEAL-2, the second Phase 3 trial evaluating Elegrobart in patients with chronic thyroid eye disease, are expected in the second quarter (Q2) of 2026.Following this, Viridian plans to submit a Biologics License Application (BLA) to the U.S. FDA in Q1 2027. A BLA is a formal request submitted to the U.S. Food and Drug Administration (FDA) asking for approval to sell a biologic drug.<a href="https://stocktwits.com/symbol/VRDN">VRDN stock</a> is down 12% year-to-date, but up 87% over the past 12 months. The SPDR S&amp;P Biotech ETF (XBI) is up 40% over the past 12 months, while the iShares Russell 2000 ETF (IWM) is up 19%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/roma-stock-soars-100m-share-repurchase-program/cZERVIhRIZs">ROMA Stock Shot Up 10% Today – Everything To Know About Its Gigantic Share Repurchase Program</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Trading digital board showing the data on global stock market crash. | Image source: Getty Images

VRDN Stock Plummeted 41% Pre-Market Today — What Did Its Phase 3 Active Thyroid Eye Disease Trial Reveal?

Viridian stated that while Elegrobart was generally well tolerated in the four and eight-week dosing regimens, the phase 3 trial showed low rates of hearing impairment.

Equity

Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL1 Clinical Trial in Active Thyroid Eye Disease

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for serious and rare diseases, today announced positive topline data from the elegrobart REVEAL-1 phase 3 clinical trial in patients with...

Hudson Bay Capital Management LP Raises Stake in Viridian Therapeutics, Inc. $VRDN

Hudson Bay Capital Management LP raised its stake in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 46.6% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 175,251 shares of the company's...

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know

Key PointsKynam Capital sold 2,957,386 shares of Viridian Therapeutics in the fourth quarter; the estimated trade size was $81.11 million based on quarterly average pricing...

Commodore Capital LP Cuts Stake in Viridian Therapeutics, Inc. $VRDN

Commodore Capital LP reduced its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 34.4% during the third quarter, according to its most recent disclosure with the...

Viridian Therapeutics, Inc. $VRDN Stock Holdings Reduced by Rosalind Advisors Inc.

Rosalind Advisors Inc. lowered its position in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 14.3% during the third quarter, according to its most recent Form 13F filing with the SEC...

Wedbush Reaffirms Outperform Rating for Viridian Therapeutics (NASDAQ:VRDN)

Wedbush reissued an "outperform" rating and issued a $44.00 price target on shares of Viridian Therapeutics in a research report on Wednesday...

Viridian Therapeutics (NASDAQ:VRDN) Downgraded to "Sell" Rating by Wall Street Zen

Wall Street Zen downgraded shares of Viridian Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday...

Viridian Therapeutics, Inc. is a biopharmaceutical company that develops medicines for autoimmune and rare diseases. It uses antibody discovery and protein engineering to create new therapies. The company is advancing late-stage IGF-1R therapies for thyroid eye disease (TED) and developing a potential TSHR-targeted treatment for TED and Graves’ disease. In addition, it is developing FcRn inhibitors, including VRDN-006 and VRDN-008, for multiple autoimmune diseases. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Fred Wilson - Union Square Ventures

Abigail Johnson - Fidelity

Jim Cramer - Media Personality

Josh Brown - Ritholtz Wealth Management

A lifetime achievement for industry titans. This honor is reserved for an individual whose groundbreaking contributions have shaped the investing landscape and how we engage with the markets.

Stocktwits

Stocktwits Polls

Investors are reacting to the Phase 3 REVEAL-1 trial data, which showed high responder rates despite an unexpected stock sell-off.

The stock plummeted over 35% pre-market as analysts and traders question the drug's long-term competitive edge in the TED market.

VRDN
Viridian Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest VRDN News

VRDNViridian Therapeutics Inc